A
AcuamarkDx
Dedicated to developing technology which allows for blood-based screening and early detection of cancer
About AcuamarkDx
Acuamark Diagnostics is at the forefront of the global fight against cancer, specializing in the development of highly accurate blood tests for early cancer detection. The company serves healthcare providers and patients by offering advanced screening solutions that identify cancer markers at early stages, significantly improving treatment outcomes. Operating within the biotechnology and healthcare sectors, Acuamark employs a business-to-business (B2B) model, partnering with medical institutions and laboratories. Revenue is generated through the sale of its proprietary assays and sequencing technologies, which are designed to be both cost-effective and scalable. The company's core technology includes Eagle iSeq and Eagle i5 assays, which enable deep sequencing analysis and single molecule detection of cancer markers, such as mutations, methylation, and various RNA types. Founded by a team of seasoned scientific and business professionals, Acuamark Diagnostics leverages over 20 years of expertise in DNA mutation detection, DNA microarrays, DNA sequencing, and colorectal cancer genomics. This multidisciplinary approach ensures that their products remain at the cutting edge of cancer diagnostics.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- New York City, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 67.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Spinout, Biotech and Pharma, medical testing, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning AcuamarkDx.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2022 | $11M | $45M | Bruker · Del Vecchio Family Foundation | ↗ |
| EARLY VCEquity / VC | Sep 2019 | $2.3M | $9.2M | Undisclosed | — |
Growth signals
Latest recorded traffic for AcuamarkDx is 1.8K monthly website visits, up 116.9% over the last three months. AcuamarkDx's team declined 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- DFDel Vecchio Family Foundation
Bruker
Other known investors3 additional known investors
Cornell Tech
Cornell University
XLerateHealth
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AcuamarkDx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AcuamarkDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.